An observational, prospective, open-label study to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Acronyms AZURE
- Sponsors Novartis
- 06 Mar 2013 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
- 07 Mar 2011 New trial record